JPWO2022117045A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022117045A5
JPWO2022117045A5 JP2023533951A JP2023533951A JPWO2022117045A5 JP WO2022117045 A5 JPWO2022117045 A5 JP WO2022117045A5 JP 2023533951 A JP2023533951 A JP 2023533951A JP 2023533951 A JP2023533951 A JP 2023533951A JP WO2022117045 A5 JPWO2022117045 A5 JP WO2022117045A5
Authority
JP
Japan
Prior art keywords
sequence seq
variable region
amino acid
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552198A (ja
Publication date
Priority claimed from CN202011402180.8A external-priority patent/CN114573703A/zh
Application filed filed Critical
Publication of JP2023552198A publication Critical patent/JP2023552198A/ja
Publication of JPWO2022117045A5 publication Critical patent/JPWO2022117045A5/ja
Pending legal-status Critical Current

Links

JP2023533951A 2020-12-02 2021-12-02 T細胞アダプター治療剤の開発及び使用 Pending JP2023552198A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011402180.8 2020-12-02
CN202011402180.8A CN114573703A (zh) 2020-12-02 2020-12-02 一种t细胞衔接器治疗剂的开发和应用
PCT/CN2021/135121 WO2022117045A1 (fr) 2020-12-02 2021-12-02 Développement et utilisation d'un agent thérapeutique d'activation de lymphocytes t

Publications (2)

Publication Number Publication Date
JP2023552198A JP2023552198A (ja) 2023-12-14
JPWO2022117045A5 true JPWO2022117045A5 (fr) 2024-06-06

Family

ID=81770769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533951A Pending JP2023552198A (ja) 2020-12-02 2021-12-02 T細胞アダプター治療剤の開発及び使用

Country Status (7)

Country Link
EP (1) EP4257607A1 (fr)
JP (1) JP2023552198A (fr)
KR (1) KR20230117178A (fr)
CN (2) CN114573703A (fr)
AU (1) AU2021390122A1 (fr)
CA (1) CA3200652A1 (fr)
WO (1) WO2022117045A1 (fr)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (fr) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-aminobenzyl ether dans des agents d'administration de medicaments
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
EP1725586B1 (fr) 2004-03-02 2015-01-14 Seattle Genetics, Inc. Anticorps partiellement charges et procedes de conjugaison desdits anticorps
CA2586909A1 (fr) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatines comportant une unite d'acide aminobenzoique au n-terminal
JP4658125B2 (ja) 2005-06-28 2011-03-23 パイオニア株式会社 放送受信装置、妨害検出装置および妨害検出方法
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
ME03440B (fr) * 2011-05-21 2020-01-20 Macrogenics Inc Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途

Similar Documents

Publication Publication Date Title
JP7410143B2 (ja) 二重特異性抗体及びその用途
JP6261341B2 (ja) Cd74に対するヒト抗体および抗体−薬物コンジュゲート
KR20160007478A (ko) 인간 IgG1 Fc 영역 변이체 및 그의 용도
WO2021088838A1 (fr) Molécule se liant spécifiquement à cd39 et son utilisation
KR20080105111A (ko) 항 EphA4 항체의 효과기 기능을 이용한 세포 손상 방법
US20230330257A1 (en) Development of drug therapeutic agent containing adaptor and use thereof
WO2022105924A1 (fr) Anticorps bispécifique et son utilisation
EP4273169A1 (fr) Développement et utilisation d'un agent de blocage d'anticorps à fonction améliorée
WO2022117045A1 (fr) Développement et utilisation d'un agent thérapeutique d'activation de lymphocytes t
US11884729B2 (en) Anti-L1CAM antibodies and uses thereof
US20240043568A1 (en) Development of new tumor engager therapeutic drug and use thereof
JPWO2022117045A5 (fr)
WO2023125652A1 (fr) Anticorps bispécifique contre cd40 et cldn18.2 et son application
JP2024508048A (ja) Siglec-15結合タンパク質の調製およびその使用